EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma

Maria Reviejo, Elisa Lozano, Raul Mendez, Luis M Gonzalez, Rocio I R Macias, Oscar Briz, Jose J G Marin, Maitane Asensio

Biochemical Pharmacology · 2026

DOI: 10.1016/j.bcp.2026.117927 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Maria Reviejo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IB…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, RNA-Binding Proteins, Bile Duct Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission, European Cooperation in Science and Technology, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Expression of poly(rC)-binding protein 2 (PCBP2) is altered in various cancers. This study aimed to assess its role in the development of the malignant phenotype in cholangiocarcinoma (CCA) cells. PCBP2 mRNA levels in CCA (n = 35) and adjacent non-tumor (NT) tissue (n = 9) were analyzed in silico using the TCGA-CHOL database. PCBP2 expression was also measured experimentally (RT-qPCR, WB, and IHC) in clinical samples from intrahepatic CCA (iCCA; n = 17), extrahepatic CCA (eCCA; n = 17), and NT tissue (n = 14). The relationship of PCBP2 expression with clinicopathological features was investigated. The PCBP2 gene was silenced in CCA-derived cells using lentiviral vectors carrying shRNAs. After transduction, cell viability (MTT assay), colony formation (crystal violet staining), cell cycle (flow cytometry), proliferation and migration (holographic microscopy), and transcriptome profiling (RNA-seq) were assessed. The results indicated that PCBP2 was highly expressed in CCA and that its expression correlated with metastasis and poor progression-free survival. Silencing PCBP2 in CCA cells did not alter the response to anti-CCA drugs (cisplatin, oxaliplatin, gemcitabine, 5-fluorouracil, and sorafenib) but reduced cell viability and proliferation, impaired colony formation, and inhibited migration. Transcriptomic analysis following PCBP2 silencing revealed the downregulation of several oncogenic genes (DHRS3, NRP2, MEX3A, and PCGF2). Electrophoretic mobility shift assay (EMSA) demonstrated that PCBP2 binds to the DHRS3 3'UTR, suggesting a role for PCBP2 in the post-transcriptional regulation of its target genes. In conclusion, PCBP2 promotes the malignant phenotype in CCA, highlighting its potential as a target for the development of future pharmacological treatments for patients with this cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaRNA-Binding ProteinsBile Duct NeoplasmsHumansCell Line, TumorPhenotypeGene Expression Regulation, NeoplasticCell ProliferationMaleFemaleCell MovementMiddle AgedCell Survival

Stichwörter der Autor:innen

Biliary tract cancerMigrationPCBP2Proliferation

Substanzen

PCBP2 protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain; Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Centro de Investigación Biomédica en Red de en…
  • Experimental Hepatology and Drug Targeting (HEVEPHARM), University of Salamanca, Salamanca, Spain.
  • Service of General and Gastrointestinal Surgery, University Hospital of Salamanca, IBSAL, Salamanca, Spain.

Förderung

  • European Commission
  • European Cooperation in Science and Technology
  • Instituto de Salud Carlos III
  • Gobierno de España Ministerio de Ciencia e Innovación
  • Government of Castile and León
  • Spanish Association Against Cancer Scientific Foundation

Zitieren

APA

Reviejo, M., Lozano, E., Mendez, R., Gonzalez, L. M., Macias, R. I. R., Briz, O., Marin, J. J. G., & Asensio, M. (2026). Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.117927

Vancouver

Reviejo M, Lozano E, Mendez R, Gonzalez LM, Macias RIR, Briz O, et al. Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.117927

BibTeX
@article{Reviejo2026,
  author = {Reviejo, Maria and Lozano, Elisa and Mendez, Raul and Gonzalez, Luis M and Macias, Rocio I R and Briz, Oscar and Marin, Jose J G and Asensio, Maitane},
  title = {Impact of poly(rC)-binding protein 2 (PCBP2) on the malignant phenotype of cholangiocarcinoma},
  journal = {Biochemical Pharmacology},
  year = {2026},
  doi = {10.1016/j.bcp.2026.117927}
}
Kostenlos starten →